News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
689,255 Results
Type
Article (39910)
Company Profile (293)
Press Release (649052)
Section
Business (206278)
Career Advice (2016)
Deals (35662)
Drug Delivery (81)
Drug Development (81486)
Employer Resources (169)
FDA (16069)
Job Trends (14959)
News (347826)
Policy (32699)
Tag
Academia (2557)
Africa (741)
Alliances (49861)
Alzheimer's disease (1158)
Approvals (15988)
Arizona (177)
Artificial intelligence (70)
Asia (37744)
Australia (6264)
Bankruptcy (353)
Best Places to Work (11356)
Biotechnology (215)
C2C Services and Suppliers (79205)
California (1924)
Canada (942)
Cancer (499)
Career advice (1682)
Cell therapy (124)
China (153)
Clinical research (63870)
Collaboration (146)
Colorado (79)
Compensation (83)
Connecticut (76)
COVID-19 (2515)
Cystic fibrosis (73)
Data (320)
Diabetes (82)
Diagnostics (6007)
Drug pricing (64)
Earnings (84153)
Employer resources (144)
Europe (81260)
Events (110621)
Executive appointments (159)
FDA (16300)
Florida (269)
Funding (151)
Gene therapy (94)
GLP-1 (515)
Government (4315)
Healthcare (18704)
Hotbed/Location (486448)
Illinois (279)
Indiana (149)
Infectious disease (2544)
Inflammatory bowel disease (92)
Interviews (309)
IPO (16317)
Job creations (3734)
Job search strategy (1445)
Kansas (98)
Layoffs (396)
Legal (7903)
Lung cancer (111)
Manufacturing (92)
Maryland (403)
Massachusetts (1570)
Medical device (13065)
Medtech (13070)
Mergers & acquisitions (19221)
Metabolic disorders (255)
Michigan (124)
Minnesota (216)
Neuroscience (1308)
New Jersey (594)
New York (603)
NextGen Class of 2024 (6549)
Non-profit (4485)
North Carolina (610)
Northern California (837)
Obesity (152)
Ohio (107)
Opinion (183)
Patents (78)
Pennsylvania (589)
People (56882)
Pharmaceutical (65)
Phase I (19858)
Phase II (28178)
Phase III (20907)
Pipeline (115)
Postmarket research (2555)
Preclinical (8448)
Press Release (71)
Radiopharmaceuticals (231)
Rare diseases (131)
Real estate (6045)
Recruiting (65)
Regulatory (21400)
Research institute (2336)
Resumes & cover letters (351)
South America (1126)
Southern California (778)
Startups (3666)
Texas (246)
United States (8765)
Vaccines (480)
Washington State (256)
Weight loss (132)
Date
Last 7 days (616)
Last 30 days (2404)
Last 365 days (37388)
2024 (26603)
2023 (40429)
2022 (51638)
2021 (56114)
2020 (54484)
2019 (46912)
2018 (35348)
2017 (32528)
2016 (32053)
2015 (38032)
2014 (31812)
2013 (26848)
2012 (29162)
2011 (29834)
2010 (27936)
689,255 Results for "plandai biotechnology inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
Plandai Biotechnology, Inc. Announces Rescission of Material Definitive Agreement with Good Salt, LLC
Plandai Biotechnology, Inc. announces the rescission of a material definitive agreement with Good Salt, LLC due to the material failure of consideration in the transaction.
August 1, 2023
·
1 min read
Business
Plandai Biotechnology, Inc. Announces Entry into Material Share Exchange Agreement with Good Salt, LLC
Plandai Biotechnology, Inc. (OTC PINK:PLPL) announces it has entered into a binding memorandum of understanding to close a share exchange agreement with Good Salt, LLC, a Florida limited liability company.
March 20, 2023
·
4 min read
BioMidwest
ByoPlanet Announces Completion of Share Exchange Agreement with Plandai Biotechnology
Plandai Biotechnology, Inc. announce the completion of a share exchange agreement whereby PLPL shall acquire one hundred percent of the issued and outstanding ByoPlanet Interests and ByoPlanet’s fixed tangible and intangible assets in exchange for all authorized, issued, and outstanding PLPL Preferred Common Shares and Common Stock.
May 17, 2023
·
5 min read
Deals
Plandai Biotechnologies, Inc. Announces Termination of Asset Acquisition Agreement with EV Hotel, Updates on Status of Independent Audit
Plandai Biotechnology, Inc. announces the termination of its previously announced asset acquisition agreement with EV Hotel Corp., a Georgia corporation.
January 4, 2023
·
1 min read
Policy
Plandai Biotechnologies, Inc. Announces Entry into Non-Binding Letter of Intent, Updates on Status of Independent Audit
Plandai Biotechnology, Inc. announces its entry into a non-binding letter of intent with EV Hotel Corp., a Georgia corporation.
October 6, 2022
·
3 min read
BioMidwest
Following Completed Share Exchange Agreement with ByoPlanet, Plandai Announces Material Rebranding to Disinfectant Industry Focus
Plandai Biotechnology is pleased to announce a comprehensive rebranding initiative following the successful completion of its share exchange agreement with ByoPlanet, LLC.
May 18, 2023
·
4 min read
BioMidwest
Third-Party Valuation Firm Provides Estimated Valuation of ByoPlanet’s (A Subsidiary Of Plandai – $PLPL) Business and Assets
ByoPlanet, a wholly owned subsidiary of Plandai Biotechnology, Inc., a leading innovator in revolutionary cleaning technology, announced the completion of a third-party valuation firm’s estimates of ByoPlanet’s business and assets based on ByoPlanet’s unaudited financial statements and internal projections.
May 31, 2023
·
8 min read
Business
Plandai Biotechnology, Inc. Announces Termination of Non-Binding Letter of Intent
Plandai Biotechnology, Inc. announces the termination of its non-binding letter of intent dated May 23, 2022, with Ms. Jessie Chiang, license holder of the worldwide rights, exclusive of Taiwan, of the Puriblood Leukocyte Reduction Blood Filtration System.
July 27, 2022
·
1 min read
Business
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
UNITY Biotechnology, Inc. reported financial results for the first quarter ended March 31, 2024.
May 14, 2024
·
7 min read
Deals
Nika Pharmaceuticals, Inc. (NKPH) Merges With Nika Biotechnology, Inc.
Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH) announces its merger with Nika BioTechnology, Inc., effective as of March 1, 2024.
March 20, 2024
·
2 min read
1 of 68,926
Next